Abstract 192P
Background
Experimental and clinical studies have shown an increase in the level of interleukin-6 (IL-6) in the blood plasma and other cytokines in obstructive jaundice. The combination of a persistent increase in cytokines and an extended acute response phase is associated with a decrease in protein calories, leading to surgical complications and death.
Methods
The study involved 41 patients treated at the Gastroenterology department in 1st Republic Clinic, Tashkent aged from 33 to 84 years old (62.8 ± 2.14) were studied, of whom 26 (63.4%) were men and 15 (36.6%) were women. The duration of the icteric period by the time of admission to the hospital averaged 28.7 ± 2.18 days. At the same time, in 6 (14.6%) patients the duration of cholestasis was up to 15 days, in 10 (24.4%) - from 15 to 30 days, in 25 (61.0%) - more than 1 month. Percutaneous transhepatic cholangiography (PTCH) with per-cutaneous transhepatic cholangiostomy (PTCHS) was performed for all patients, regardless of the localization of the tumor process. The level of IL-6 in serum and bile was determined by ELISA method.
Results
The concentration of IL-6 before the overlap of PTCH in the serum was higher than normal, averaging 152.65 ± 16.3 pg/ml. Immediately after the overlaying of PTCH in bile, this indicator was on average 68.58 ± 7.24 pg/ml. The high content of IL-6 in serum and bile testified to a pronounced endogenous intoxication of the body. The concentration of IL-6 in the initial day after the imposition of PTCH in serum decreased to 32.9%. In the following days, this indicator remained virtually unchanged, but on the 6th day of observation, there was a slight increase in his blood. In the bile at the same time, the concentration of IL-6 decreased by 17.1%. These indicators remained virtually unchanged up to 6 days of observation. On the 14th day, the decrease in the level of IL-6 in the blood compared to baseline was 64.4%, and in the bile 54.3% (P < 0.001).
Conclusions
Thus, the determination of IL-6 in the blood and in the bile makes it possible to more objectively evaluate the tumor process and the cytokine-induced endogenous intoxication to the response of the therapeutic measures taken in biliopancreatoduodenal tumors complicated by the mechanical jaundice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract